Discounted Cash Flow
Biofrontera Inc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2020 | $18.8m | $-11.0m | — | -58.3% | — |
| 2021 | $24.1m (27.9%) | $-37.7m (-243.3%) | $-3.0k | -156.5% (-168.5%) | $-4.28 |
| 2022 | $28.5m (18.4%) | $-640.0k (98.3%) | $-640.0k (-21233.3%) | -2.2% (98.6%) | $-0.61 (85.7%) |
| 2023 | $34.1m (19.4%) | $-20.1m (-3045.5%) | $-24.9m (-3790.6%) | -59.1% (-2534.9%) | $-13.02 (-2034.4%) |
| 2024 | $37.3m (9.5%) | $-17.8m (11.8%) | $45.0k (100.2%) | -47.6% (19.5%) | $-3.22 (75.3%) |
| 2025 | $41.7m (11.7%) | $-10.5m (40.7%) | $1.4m (2942.2%) | -25.3% (46.9%) | $-1.04 (67.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.